SPIKEVAX

PreclinicalActive

0 views this week 0 watching

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myocarditis

Conditions

Myocarditis

Trial Timeline

Apr 30, 2022 → Oct 31, 2027

NCT ID

NCT06189053

About SPIKEVAX

SPIKEVAX is a preclinical stage product being developed by Moderna for Myocarditis. The current trial status is active. This product is registered under clinical trial identifier NCT06189053. Target conditions include Myocarditis.

What happened to similar drugs?

0 of 1 similar drugs in Myocarditis were approved

Approved (0) Terminated (0) Active (1)

🔄Abatacept plus + PlaceboBristol Myers SquibbPhase 3

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06130345	Preclinical	Completed	Apr 14, 2023	Feb 29, 2024	SARS-CoV-2
NCT06369272	Preclinical	Completed	Mar 1, 2023	Oct 20, 2023	Maternal Outcomes, Infant Outcomes, Pregnancy
NCT06189053	Preclinical	Active	Apr 30, 2022	Oct 31, 2027	Myocarditis

Competing Products

3 competing products in Myocarditis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Preclinical	0
Abatacept plus + Placebo	Bristol Myers Squibb	Phase 3	47
Treatment with G-CSF (Granulocyte colony stimulating factor) + Placebo saline	Rafael Holdings	Phase 2	25